Recent

% | $
Quotes you view appear here for quick access.

American Eagle Outfitters, Inc. Message Board

broad_and_south 6 posts  |  Last Activity: Jun 29, 2016 8:16 PM Member since: Oct 18, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Way oversold...my lord.

    by sdfgtyuhjiko Jun 29, 2016 3:44 PM
    broad_and_south broad_and_south Jun 29, 2016 8:16 PM Flag

    Traders use the word "oversold" in the wrong context. If there is no change in the fundamentals, meaning intrinsic valuation, and the stock goes down, it is oversold.

    However if there is a significant change in the fundamentals, a sell off happens to find the new trading level. In the case of ESPR, the fundamentals have changed.

  • Reply to

    My Prediction

    by bull_dot_com Jun 22, 2016 4:35 PM
    broad_and_south broad_and_south Jun 23, 2016 7:12 AM Flag

    Are you asleep? Steve Jobs was great at AAPL. But Musk created Paypal, TSLA, SCTY, and SpaceX. He is a wunderkind of Jobs's proportion.

    But Musk takes a step backwards with this SCTY deal.

  • broad_and_south by broad_and_south May 31, 2016 10:08 AM Flag

    Since Saturday morning, the posts on the MB have been over the top on the price ICPT will rise once the markets opened up on Tuesday. Some even had a GILD deal ready to be announced on Monday. I was chastised for offering a $145-$150 price today. I will probably not be too far off.

    I think ICPT has a bright future but it will take longer to manifest itself. Once GILD bought into Nimbus, you knew that a major liver disease company was out of play. But the real issue is Hillary and her desire to get drug prices down. VRX and Martin Shrikeli did a lot to cause this problem. ICPT's NASH potential is immature but promising, They have $700k in the bank to fund the trial. ICPT will not sell at a Hillary-degraded price. They are smart to wait. Buyers will not offer big prices until the political overhang is gone.

    All this played out last week with very poor trading in a stock about to receive FDA approval. ICPT will trade in will defined bounds until something happens to change the value of the company.

  • Reply to

    GILEAD and Nimbus Apollo

    by gmrowe May 30, 2016 5:22 AM
    broad_and_south broad_and_south May 30, 2016 11:55 AM Flag

    I think a target like REGN will fill the bill. They have growing earnings. No product overlap so the FTC will not stop the merger.

    Of course there are others, but this comes to mind.

  • Reply to

    GILEAD and Nimbus Apollo

    by gmrowe May 30, 2016 5:22 AM
    broad_and_south broad_and_south May 30, 2016 11:39 AM Flag

    The last ER for GILD was bad. The stock is in portfolios that demand performance now. Wall Street is dysfunctional this way. ICPT NASH is a few years away and an orphan indication for PBC will not move the needle. I think the Nimbus acquisition was a "tell."

  • Reply to

    GILEAD and Nimbus Apollo

    by gmrowe May 30, 2016 5:22 AM
    broad_and_south broad_and_south May 30, 2016 10:58 AM Flag

    Many people misread GILD's need to acquire. Yes they do need to buy an asset, but it must be immediately accretive to sales and earnings growth rate. Like it or not, this is the Wall Street game. In baseball, teams will acquire a hot pitcher in July or August to make a run for the pennant. This is GILD.

    I viewed the Nimbus acquisition as drafting an 18 yo into the farm team. It will take years for Nimbus to commercialize a NASH product. It would seem that GILD made a run at ICPT and backed out when the price got too steep. They then went with Nimbus.

    A new drug in a new indication is not a done deal after a successful P3 and FDA approval. There is insurance coverage, foreign markets, and side effects not seen during trials. I would rate ICPT as a promising AAA baseball player who is called up during a pennant race to fill a gap perhaps only for one start.

    Getting back to your question: GILD does not need two solutions for NASH.

AEO
18.66+0.09(+0.48%)Aug 26 4:00 PMEDT